Financial Performance - For the fiscal year ending June 30, 2025, the company's revenue was approximately RMB 90.2 million, a significant increase from RMB 47.6 million in the previous fiscal year[3] - The profit attributable to the owners for the fiscal year 2025 was approximately RMB 22.7 million, down from RMB 200 million in fiscal year 2024[4] - The total comprehensive income attributable to the owners for fiscal year 2025 was approximately RMB 28.2 million, compared to RMB 204 million in fiscal year 2024[4] - Basic earnings per share for fiscal year 2025 were RMB 2.75, a decrease from RMB 29.79 in fiscal year 2024[4] - The company reported a gross profit of RMB 8.2 million for fiscal year 2025, compared to RMB 1.9 million in fiscal year 2024[4] - The group reported a total profit of RMB 30,197,000 for the year ending June 30, 2025, compared to RMB 11,705,000 in the previous year, marking an increase of 157.5%[19] - The company reported a net profit of RMB 22,711,000 for 2025, a significant decrease from RMB 200,013,000 in 2024[31] Revenue Breakdown - Revenue from the timber-related products was RMB 36,633,000, up from RMB 32,521,000, indicating an increase of 34.5% year-over-year[15] - Revenue from ginseng-related products surged to RMB 39,467,000 from RMB 15,085,000, reflecting a growth of 161.5%[15] - The company’s total revenue from external customers in China reached RMB 76,100,000 in 2025, up from RMB 47,606,000 in 2024, an increase of 59.8%[25] - Ginseng business revenue reached approximately RMB 39.5 million in the 2025 fiscal year, with RMB 25 million from supplier purchases and RMB 14.5 million from self-cultivated ginseng[39] - Health product manufacturing and trading business generated revenue of approximately RMB 14.1 million in the 2025 fiscal year[40] Assets and Liabilities - The total assets less current liabilities increased to RMB 162.3 million in fiscal year 2025, up from RMB 128.9 million in fiscal year 2024[5] - The net assets of the company increased to RMB 46.7 million in fiscal year 2025, compared to RMB 12.9 million in fiscal year 2024[6] - Total assets increased to RMB 205,417,000 in 2025 from RMB 178,166,000 in 2024, representing a growth of 15.3%[22] - Total liabilities decreased to RMB 158,697,000 in 2025 from RMB 165,203,000 in 2024, a reduction of 3.1%[22] Capital Structure - The capital-to-debt ratio improved to approximately 77.3% in fiscal year 2025, down from 92.7% in fiscal year 2024, representing a decrease of 15.4 percentage points[3] - The capital-to-debt ratio as of June 30, 2025, was approximately 77.3%, a decrease from 92.7% as of June 30, 2024[57] Dividends and Share Structure - The company did not recommend any dividend distribution for fiscal year 2025, consistent with fiscal year 2024[3] - No final dividend has been recommended for the fiscal year 2025, consistent with the previous fiscal year[64] - A share consolidation was approved on July 4, 2025, reducing the total number of issued shares from 859,242,204 to 85,924,220[60] - The total number of issued shares has been adjusted from 859,242,204 to 85,924,220 following the share consolidation effective July 8, 2025[62] - The company announced a conditional placement of up to 17,000,000 new shares at a price of HKD 0.28 per share, aiming to raise approximately HKD 4.63 million, which represents an increase of about 16.52% in the enlarged issued share capital[63] Operational Developments - The company began operations in the health product trading business in November 2024, indicating a strategic expansion into new markets[8] - The group obtained harvesting permits for 18,016 cubic meters for the 2025 calendar year, an increase from the previous year's harvesting volume[41] - The group plans to gradually reduce reliance on suppliers for aged ginseng as it builds sufficient inventory of self-cultivated ginseng[41] - The group successfully planted the first batch of Epimedium on its owned land in June 2024, with an additional 28 acres planted in July 2024[42] Financial Reporting Standards - The group anticipates the adoption of new Hong Kong Financial Reporting Standards will impact its accounting policies starting from the first period after their effective date[13] - The new Hong Kong Financial Reporting Standard No. 18 will introduce new presentation and disclosure requirements in the consolidated income statement, effective from January 1, 2027[13] - The group is currently assessing the detailed impact of the new standards on its consolidated financial statements[13] - The group expects that other amendments to the Hong Kong Financial Reporting Standards will not have a significant impact on its consolidated financial statements[13] Expenses and Costs - Administrative expenses decreased by approximately 27.0% to RMB 15.7 million in fiscal year 2025, down from RMB 21.5 million in fiscal year 2024, mainly due to a reduction in legal expenses[47] - Financing costs increased by approximately 8.5% to RMB 3.5 million in fiscal year 2025, compared to RMB 3.2 million in fiscal year 2024[49] - The company incurred a total cost of RMB 36,633,000 for harvested timber in 2025, compared to RMB 32,522,000 in 2024, an increase of 12.9%[29] Trade Receivables and Payables - Trade receivables increased to RMB 33,796,000 in 2025 from RMB 17,343,000 in 2024, representing a growth of 95.5%[32] - Trade payables increased to RMB 29,029,000 in 2025 from RMB 16,304,000 in 2024, reflecting a growth of 77.6%[32] - The average credit period granted to trade customers remains at 120 days for both 2024 and 2025[32] - The average credit period for purchasing goods is maintained at 90 days[32] Audit and Compliance - The audit committee, consisting of three independent non-executive directors, reviewed the financial reporting process and internal control systems, and has no objections to the group's consolidated financial performance as reported[71]
中国健康科技集团(01069) - 2025 - 年度业绩